Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADORA3 | P0DMS8 | 12/20 | 0.50 |
| ▸ | ADORA2A | P29274 | 9/20 | 0.50 |
| ▸ | ADORA1 | P30542 | 9/20 | 0.50 |
| ▸ | ADORA2B | P29275 | 4/20 | 0.50 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.39 |
| ▸ | PRMT5 | O14744 | 1/20 | 0.38 |
| ▸ | WDR77 | Q9BQA1 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4426285 | 1.00 | ADORA3 (0.50) | ADORA3ADORA2AADORA1ADORA2BALOX15 | |
| SCHEMBL13598823 | 1.00 | ADORA3 (0.50) | ADORA3ADORA2AADORA1ADORA2BALOX15 | |
| SCHEMBL13598668 | 1.00 | ADORA3 (0.50) | ADORA3ADORA2AADORA1ADORA2BALOX15 | |
| SCHEMBL14089579 | 0.88 | ADORA3 (0.50) | ADORA3ADORA2AADORA1ADORA2BALOX15 | |
| SCHEMBL4432753 | 0.88 | ADORA3 (0.50) | ADORA3ADORA2AADORA1ADORA2BALOX15 | |
| SCHEMBL13598667 | 0.88 | ADORA3 (0.50) | ADORA3ADORA2AADORA1ADORA2BALOX15 | |
| SCHEMBL16174393 | 0.85 | ADORA2A (0.61) | ADORA3ADORA2AADORA1ADORA2BPRMT5 | |
| SCHEMBL4423328 | 0.85 | ADORA2A (0.50) | ADORA3ADORA2AADORA1ADORA2BALOX15 | |
| SCHEMBL13598822 | 0.85 | ADORA2A (0.50) | ADORA3ADORA2AADORA1ADORA2BALOX15 | |
| SCHEMBL1737331 | 0.85 | ADORA2A (0.61) | ADORA3ADORA2AADORA1ADORA2BPRMT5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7425547-B2 | Nucleoside derivatives for treating hepatitis C virus infection | GENELABS TECHNOLOGIES, INC. (US) | 2008-09-16 | — | — | US | disclosed |